Europe – NICE rejects Novartis’ CAR-T Kymriah for adult lymphoma

The National Institute for Health and Care Excellence has turned down NHS funding for use of Novartis’ CAR-T therapy Kymriah in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The draft guidance recommends against its use for adults after two or more lines of systemic therapy, concluding that it is not cost effective for routine funding or use within the Cancer Drugs Fund (CDF).

A key sticking point is the fact that there is no data comparing Kymriah (tisagenlecleucel-T) to salvage chemotherapy, the most common treatment currently used, making it difficult to determine the exact benefits of the therapy, NICE said.

The committee also noted the degree of side effects a person may experience from Kymriah and the need for extensive monitoring by trained specialists.

These were also key factors behind the Institute’s earlier rejection of Gilead’s CAR-T therapy Yescarta (axicabtagene ciloleucel) for diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma…